Acadia Healthcare Co Inc (ACHC) Shares Fall 4.3% -- What GF Scor
Acadia Healthcare Co Inc (ACHC) shares dropped 4.3% to $23.03 on May 21, 2026, despite a year-to-date gain of 62.3%. The company is considered undervalued with a GF Value™ of $48.61, but a GF Score™ of 70/100 and a 'possible value trap' warning suggest caution, especially given the lack of insider transactions in the last three months. Investors are advised to consider the company's financial health alongside its favorable valuation metrics.
Orlando Health opens new Apopka behavioral hospital as Longwood campus eyes redevelopment
Orlando Health is opening a new 144-bed behavioral health hospital in Apopka, replacing its former Longwood site. The new campus will expand behavioral health and substance abuse services in Central Florida. This move coincides with potential redevelopment plans for the previous Longwood campus.
Jury Hands Down $105M in Damages to Acadia Healthcare Entity
A San Diego jury has awarded $105 million in damages against Acadia Healthcare's Fashion Valley Comprehensive Treatment Center. The jury found that the entity wrongfully terminated a female staffer after she reported concerns about an unsafe work environment and sexual harassment, deeming the firing as retaliation. This verdict comes as Acadia Healthcare faces other legal challenges, including a recent $1.09 billion loss in 2025 and ongoing investigations by the U.S. Department of Justice and the SEC.
Acadia Healthcare Co stock (US0048111059): jury verdict shocks market after strong earnings
Acadia Healthcare Co (ACHC) is facing market volatility after a subsidiary was hit with a $105 million jury verdict in an employment-related lawsuit, despite the company previously reporting solid quarterly earnings. The lawsuit concerns alleged retaliation and wrongful conduct, and Acadia Healthcare plans to challenge the decision. This legal issue introduces uncertainty for investors, even as the underlying demand for behavioral health services remains strong and the company has historically shown good operational performance.
[8-K] Acadia Healthcare Company, Inc. Reports Material Event
Acadia Healthcare Company, Inc. (ACHC) reported a material event via an 8-K filing regarding a lawsuit against its indirect subsidiary, San Diego Health Alliance, Inc. d/b/a Fashion Valley CTC. A jury awarded a former employee $35 million in compensatory and $70 million in punitive damages for retaliatory termination. Both the Company and Fashion Valley vehemently disagree with the verdict and intend to challenge it through post-trial motions and potential appeals, citing that the award far exceeds expectations for comparable cases.
Acadia Healthcare subsidiary faces $105 million jury verdict in employment lawsuit
A subsidiary of Acadia Healthcare Company, Inc. (NASDAQ:ACHC), San Diego Health Alliance, Inc. (operating as Fashion Valley CTC), has been ordered by a California jury to pay $105 million in damages in an employment lawsuit. The lawsuit was filed by a former employee alleging retaliatory termination, which Fashion Valley denied. Acadia Healthcare, though not directly party to the lawsuit, plans to challenge the verdict, which presents a significant financial challenge given its market capitalization and total debt.
Acadia Healthcare gains as major investor urges strategic review
Acadia Healthcare's stock price increased after one of its major shareholders, Pontus Capital, called for a strategic review of the company's operations. Pontus Capital, which holds a significant stake, believes that such a review could unlock substantial value for other shareholders. This indicates investor pressure to explore options that could enhance the company's valuation.
Does Einhorn’s Spotlight and ESOP Share Shelf Change The Bull Case For Acadia Healthcare (ACHC)?
Acadia Healthcare (ACHC) recently filed a US$75.54 million shelf registration for an employee stock ownership plan, coinciding with investor David Einhorn highlighting the company's operational recovery and cash generation at the Sohn Investment Conference. The article examines how these events, particularly Einhorn's focus on operational discipline, could influence the investment outlook for Acadia Healthcare, considering ongoing challenges like legal investigations and Medicaid exposure. While the company projects revenue of US$3.8 billion and earnings of US$156 million by 2029, its current fair value suggests an 11% downside.
Acadia Healthcare (ACHC) price target increased by 18.24% to 28.82
Acadia Healthcare (ACHC) has seen its price target increased by 18.24% to $28.82. This adjustment reflects a positive outlook on the company's financial prospects, indicating potential growth or improved performance in the market.
Khrom group reports 5.66% stake in Acadia Healthcare (NASDAQ: ACHC)
The Khrom group has reported a 5.66% beneficial ownership stake in Acadia Healthcare (NASDAQ: ACHC) through an amended passive investment disclosure (SCHEDULE 13G/A). This amounts to 5,201,533 shares as of March 31, 2026, with the majority held directly by Khrom Investments, and a smaller portion by Eric Khrom. The filing clarifies the shared voting and dispositive power over these shares, primarily attributed to Khrom Capital and Eric Khrom through affiliated entities.
Wellington-affiliated funds disclose 9.86% stake in Acadia Healthcare (ACHC)
Wellington Management entities have disclosed a 9.86% passive stake in Acadia Healthcare (ACHC) through a Schedule 13G/A filing. This includes 9,072,942 shares of common stock, with shared voting and dispositive powers across various affiliated Wellington advisory entities. The filing indicates a beneficial ownership for their clients rather than an activist investment intent.
Acadia Healthcare Co Inc (ACHC) Stock Up 4.3% and Still Undervalued -- GF Score: 80/100
Acadia Healthcare Co Inc (ACHC) saw its stock rise by 4.3% to $27.13, yet remains undervalued according to GuruFocus's GF Value™ of $48.60, implying a 44.2% upside. Despite a strong GF Score™ of 80/100 and high momentum, investors are cautioned about a potential value trap given weaker financial strength and valuation ranks. The company's forward P/E of 18.0x is below its 5-year median, further supporting the undervaluation claim, with no recent insider trading activity.
Goldman Sachs (ACHC) reports 1.6% stake — 1.46M shares on Schedule 13G/A
Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed an amended Schedule 13G/A, reporting a 1.6% stake in Acadia Healthcare Company, Inc. This stake, totaling 1,464,125.72 shares, includes shared voting power of 1,453,488.72 shares and shared dispositive power of 1,454,430.72 shares, as of March 31, 2026. The filing indicates a passive investment and was jointly signed by Sam Prashanth on April 24, 2026.
The Technical Signals Behind (ACHC) That Institutions Follow
This article analyzes Acadia Healthcare Company Inc. (ACHC) using AI models to identify technical signals relevant to institutional trading strategies. It highlights weak near and mid-term sentiment, a neutral long-term outlook, and presents specific trading strategies with entry points, targets, and stop losses based on price signals and risk-reward ratios.
[Form 4] Acadia Healthcare Company, Inc. Insider Trading Activity
Acadia Healthcare director Vicky B. Gregg reported receiving a stock award of 6,331 shares of common stock on May 6, 2026, at no cash cost per share. This transaction increased her direct holdings to 42,628 shares. The awarded shares will vest over three years in equal yearly installments, beginning May 6, 2027.
[Form 4] Acadia Healthcare Company, Inc. Insider Trading Activity
This article details a recent insider trading activity for Acadia Healthcare Company, Inc. (ACHC) as reported in a Form 4 filing. Michael Fucci, a Director, acquired 6,331 shares of common stock at a price of $0.00, increasing his total holdings to 28,152 shares directly owned. The shares are related to a grant/award and will vest over a 3-year period starting May 6, 2027.
[Form 4] Acadia Healthcare Company, Inc. Insider Trading Activity
Acadia Healthcare director Reeve B. Waud received two stock awards totaling 15,907 shares on May 6, 2026, including shares in lieu of his 2026 annual cash retainer, as reported in a Form 4 SEC filing. These shares vest over a three-year period, starting May 6, 2027. Following these transactions, Waud directly holds 66,283 shares and indirectly holds 653,015 shares through various trusts and Waud Capital Partners, L.L.C.
Acadia Healthcare Co stock (US0048111059): Analyst upgrade and short interest in focus
Acadia Healthcare Co (ACHC) is gaining investor attention due to a recent analyst upgrade to "strong buy" and significant short interest, even as its stock nears a 52-week high. The company, which operates behavioral health and addiction treatment facilities, benefits from strong demand in an undersupplied market. While analysts are divided on valuation, its growth is driven by capacity expansion and operational execution rather than high-tech innovation.
10 Best Performing Healthcare Stocks So Far in 2026
This article highlights Acadia Healthcare Company, Inc. (NASDAQ: ACHC) as one of the top-performing healthcare stocks in 2026, noting its 76.84% year-to-date share price gain. The company recently received upgraded ratings and increased price targets from RBC Capital and Raymond James following a strong fiscal Q1 earnings beat and raised outlook. Analysts believe Acadia Healthcare will continue to perform well through strategic facility management and underlying growth.
10 Best Performing Healthcare Stocks So Far in 2026
This article highlights Acadia Healthcare Company, Inc. (NASDAQ:ACHC) as one of the best-performing healthcare stocks in 2026, with a year-to-date share price gain of 76.84%. The company received positive rating updates from RBC Capital and Raymond James following its strong fiscal Q1 earnings beat and an increase in its 2026 EBITDA and earnings outlook. Analysts anticipate rising estimates and a higher multiple for ACHC as it focuses on improving underperforming facilities and achieving modest underlying growth.
Assessing Whether Acadia Healthcare Company (ACHC) Is Overvalued Or Undervalued After Its Recent Share Price Rebound
Acadia Healthcare Company (ACHC) has experienced recent share price volatility, with a significant rebound of 86% in the past three months, prompting questions about its current valuation. While one common narrative suggests the stock is 111.6% overvalued with a fair value of $11.94, a discounted cash flow model indicates a future cash flow value of $88.62 per share, suggesting it might be undervalued. Investors are presented with conflicting valuations, highlighting the importance of thorough analysis beyond a single metric.
Acadia Healthcare shareholders elect directors and approve compensation plan
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) shareholders elected three Class III directors and approved a second amendment to their Incentive Compensation Plan during their recent annual meeting. They also approved the compensation of named executive officers on a non-binding advisory basis and ratified Ernst & Young LLP as their independent registered public accounting firm for fiscal year 2026. This follows strong Q1 2026 financial results, which led to several analyst upgrades and price target increases despite recent premarket stock depreciation.
Acadia Healthcare shareholders elect directors and approve compensation plan
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) shareholders elected three Class III directors, approved a second amendment to the company’s Incentive Compensation Plan, and ratified Ernst & Young LLP as their independent accounting firm. They also approved the compensation of named executive officers on a non-binding advisory basis. The article also mentions recent strong Q1 2026 financial results that led to several analyst upgrades for Acadia Healthcare.
Shareholders at Acadia Healthcare (NASDAQ: ACHC) approve directors, pay and plans
Acadia Healthcare Company, Inc. held its annual meeting on May 6, 2026, where shareholders approved several key proposals. They elected three Class III directors, endorsed an amendment to the Incentive Compensation Plan, and gave non-binding approval for Named Executive Officer compensation. Additionally, shareholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Acadia Healthcare (ACHC) EVP covers tax bill with 5,063 shares
Acadia Healthcare EVP Brian Farley reported a routine tax-related share disposition. He had 5,063 shares of common stock withheld at $27.69 per share to cover tax obligations, rather than selling them on the open market. Following this transaction, Farley directly holds 139,122 shares of Acadia Healthcare common stock.
Acadia Healthcare Company Drops 5.1% After RBC Capital Maintains Outperform
Shares of Acadia Healthcare Company, Inc. (ACHC) tumbled 5.1% to $26.27 despite several analysts raising their price targets and maintaining positive ratings. RBC Capital, Guggenheim, Cantor Fitzgerald, and Barclays all increased their targets, with the average new target being $29. This paradoxical selloff suggests investor skepticism regarding the optimistic analyst outlooks or potential market repositioning.
How Margin Pressures and Softer Q2 Outlook Will Impact Acadia Healthcare Company (ACHC) Investors
Acadia Healthcare Company (ACHC) reported Q1 2026 results with reduced net income and EPS despite strong revenue, and provided a softer Q2 outlook. The company faces significant margin pressures from startup losses, bad debts, legal settlements, and rising leverage, raising concerns about its financial resilience. These factors challenge the investment narrative focused on margin recovery and highlight credit quality risks, even as the full-year revenue outlook remains reaffirmed.
How Margin Pressures and Softer Q2 Outlook Will Impact Acadia Healthcare Company (ACHC) Investors
Acadia Healthcare Company reported Q1 2026 results with reduced net income and issued softer Q2 revenue guidance, despite reaffirming its full-year outlook. The company faces significant margin pressures from startup losses, bad debts, legal settlements, and rising leverage, raising concerns about its financial resilience. These challenges prompt investors to reconsider the investment narrative and assumptions for ACHC, with analysts projecting a potentially lower fair value for the stock.
How Margin Pressures and Softer Q2 Outlook Will Impact Acadia Healthcare Company (ACHC) Investors
Acadia Healthcare reported first-quarter 2026 revenue of US$828.8 million but experienced a significant drop in net income and earnings per share, while also providing a softer second-quarter outlook. The company is facing margin pressures due to startup losses, higher bad debts, legal settlement costs, and increasing leverage, leading to concerns about earnings quality and financial resilience for investors. Despite reaffirming its full-year revenue outlook, there are red flags regarding the company's leverage, credit risk, and potential future legal costs.
Why Are Acadia Healthcare (ACHC) Shares Soaring Today
Shares of Acadia Healthcare (ACHC) surged 6.6% after Raymond James upgraded the stock to Strong Buy and raised its price target, citing solid first-quarter results and an increased 2026 financial forecast. This positive movement follows a prior drop due to a disappointing second-quarter forecast. Despite short-term volatility, the company has raised its full-year adjusted EBITDA and EPS guidance, and its stock has achieved a new 52-week high, although long-term investors from five years ago would have seen a decline.
RBC Raises Price Target on Acadia Healthcare to $31 From $28, Keeps Outperform Rating
RBC has increased its price target for Acadia Healthcare Company (ACHC) to $31 from $28, reiterating an "Outperform" rating on the stock. This adjustment reflects RBC's continued positive outlook on the behavioral healthcare services provider. The article briefly mentions other recent analyst actions and company news, including strong Q1 earnings and guidance for Q2 2026.
Is It Time To Reconsider Acadia Healthcare Company (ACHC) After This Year’s Strong Rally?
Acadia Healthcare Company (ACHC) has seen significant recent gains, with a 94.9% year-to-date return, yet its longer-term performance over 3 and 5 years shows declines. Despite these short-term rallies, a Discounted Cash Flow (DCF) analysis suggests the stock is currently undervalued by 72.9%, implying a fair value significantly higher than its current trading price of US$27.85. Additionally, its Price/Sales ratio of 0.76x is below the sector and peer averages, further supporting an undervaluation claim according to Simply Wall St's proprietary "Fair Ratio."
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Q1 2026 Earnings Call Transcript
Acadia Healthcare Company, Inc. reported strong Q1 2026 results, exceeding guidance for adjusted EBITDA and EPS, driven by revenue growth in acute inpatient psychiatric facilities and improved operational efficiencies. The company is focused on operational execution, leadership changes, and optimizing value from recent bed additions, while also addressing challenges in specialty facilities and payer denials. They updated full-year guidance, raising the adjusted EBITDA and EPS ranges.
Cantor Fitzgerald raises Acadia Healthcare stock price target on valuation
Cantor Fitzgerald has increased its price target for Acadia Healthcare (NASDAQ:ACHC) to $30.00 from $20.00, while maintaining a Neutral rating. This adjustment reflects the stock's significant appreciation, with an 82% year-to-date return, despite ongoing concerns about the operating environment and the company's debt-to-equity ratio. Acadia Healthcare recently raised its full-year guidance after reporting strong Q1 2026 earnings, though Cantor Fitzgerald remains cautious following previous guide-downs.
Acadia Healthcare Company, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:ACHC) 2026-05-01
Acadia Healthcare Company, Inc. (ACHC) released its Q1 2026 earnings, reporting an EPS of $0.37, which beat estimates by $0.11. The company also announced revenue of $828.80 million, representing a 7.57% year-over-year increase and exceeding expectations by $5.26 million. This article provides the earnings call presentation slide deck.
Acadia Healthcare EVP granted 37,510 shares | ACHC Insider Trading
Acadia Healthcare's EVP, Brian Farley, was granted 37,510 shares of common stock as part of his compensation, valued at $0.00 per share. These shares will vest over three years, beginning on April 10, 2027. Following this grant, Farley directly holds 144,185 shares of the company's common stock.
Acadia Healthcare (ACHC) Returns To Q1 Profit Challenging Deep-Loss Bear Narratives
Acadia Healthcare (ACHC) reported Q1 2026 revenue of US$828.8 million and basic EPS of US$0.05, returning to profit after a volatile 2025 that included a US$1.1 billion trailing loss. This Q1 profit challenges the bearish narrative of compounding losses, despite prior significant losses and slower revenue growth compared to the broader US market. The company's shares currently trade at a low P/S ratio and a significant discount to its DCF fair value, prompting investors to weigh this value against the backdrop of past financial struggles.
Precision Trading with Acadia Healthcare Company Inc. (ACHC) Risk Zones
This article from Stock Traders Daily provides a detailed AI-driven analysis for Acadia Healthcare Company Inc. (ACHC), highlighting strong near and mid-term sentiment but a weak long-term outlook. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for the stock.
M&T Bank Corp Has $2.10 Million Stock Holdings in Acadia Healthcare Company, Inc. $ACHC
M&T Bank Corp significantly increased its stake in Acadia Healthcare Company, Inc. (NASDAQ:ACHC) by 666.3% in Q4, acquiring an additional 128,737 shares to own a total of 148,057 shares valued at $2.10 million. Other major institutional investors like Wellington Management Group, Vanguard Group, Abrams Bison Investments, UBS Group, and State Street Corp also increased their holdings. Analysts currently have a "Hold" rating on Acadia Healthcare, with a consensus target price of $22.65, following the company's recent earnings beat and positive FY2026 guidance.
Acadia Healthcare (ACHC) Q1 2026: EPS $0.05 Miss, Revenue $828.8M Beat -- Value Trap or 62.4% Undervalued?
Acadia Healthcare Co Inc (ACHC) reported strong Q1 2026 revenue of $828.8 million, beating analyst estimates, driven by a 7.6% year-over-year growth and robust patient volumes in Acute and RTC businesses. Although GAAP diluted EPS of $0.05 missed estimates, adjusted EPS of $0.37 surpassed expectations. The company raised its full-year 2026 adjusted EBITDA and adjusted EPS guidance, indicating confidence in continued performance despite challenges in specialty treatment revenue and increased operating costs.
Acadia Healthcare Posts Q1 2026 Revenue Growth, Raises Outlook
Acadia Healthcare reported a 7.6% increase in Q1 2026 revenue, reaching $828.8 million, driven by strong acute and residential demand and expanded capacity. Although net income and adjusted EPS saw a slight decline, adjusted EBITDA improved to $144.2 million. The company has raised its full-year 2026 guidance, reflecting confidence despite facing higher interest costs and ongoing legal expenses.
Acadia Healthcare: Q1 Earnings Snapshot
Acadia Healthcare Co. reported first-quarter net income of $4.1 million, or 5 cents per share, exceeding Wall Street expectations with adjusted earnings of 37 cents per share. The company also surpassed revenue forecasts, posting $828.8 million, and provided a positive full-year earnings and revenue outlook. Acadia Healthcare's shares have seen a significant increase, rising 99% since the beginning of the year.
Acadia Healthcare (ACHC) Q1 2026: EPS $0.05 Miss, Revenue $828.8M Beat -- Value Trap or 62.4% Undervalued?
Acadia Healthcare (ACHC) reported Q1 2026 results with revenue of $828.8 million, beating analyst estimates, and adjusted EPS of $0.37, also above expectations. However, GAAP diluted EPS was $0.05, missing estimates. The company raised its full-year 2026 adjusted EBITDA and EPS guidance, despite facing challenges such as declining specialty treatment revenue and increased operating expenses.
Acadia Healthcare: Q1 Earnings Snapshot
Acadia Healthcare Co. (ACHC) reported first-quarter net income of $4.1 million, or 5 cents per share, significantly exceeding Wall Street expectations of 28 cents per share. The healthcare provider's revenue of $828.8 million also surpassed forecasts. Acadia Healthcare anticipates full-year earnings between $1.35 and $1.60 per share, with revenue ranging from $3.37 billion to $3.45 billion.
Acadia Healthcare (NASDAQ: ACHC) Q1 2026 results and higher 2026 guidance
Acadia Healthcare (NASDAQ: ACHC) reported strong Q1 2026 results, with revenue increasing 7.6% to $828.8 million and Adjusted EBITDA rising to $144.2 million. Despite a decrease in reported and adjusted EPS due to higher interest and legal settlement expenses, the company expanded its capacity and improved patient volumes. Acadia Healthcare also raised its full-year 2026 guidance for Adjusted EBITDA and Adjusted EPS, highlighting positive momentum for the remainder of the year.
Acadia Healthcare Announces First Quarter 2026 Results
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) announced its first quarter 2026 financial results, with revenue totaling $828.8 million, a 7.6% increase year-over-year, and Adjusted EBITDA of $144.2 million. The Company also raised its full-year 2026 Adjusted EBITDA and Adjusted EPS guidance, reflecting strong patient volumes and operating efficiencies. Acadia added 82 newly licensed beds during the quarter and maintained a solid cash and liquidity position.
Earnings Flash (ACHC) Acadia Healthcare Company, Inc. Posts Q1 Adjusted EPS $0.37 per Share, vs. FactSet Est of $0.26
Acadia Healthcare Company, Inc. (ACHC) announced its Q1 adjusted EPS of $0.37 per share, surpassing FactSet's estimate of $0.26. The company also reported Q1 revenue of $828.8 million, exceeding the FactSet estimate of $823.5 million. Additionally, Acadia Healthcare provided guidance for Q2, expecting adjusted EPS in the range of $0.30 - $0.40 and revenue between $835.0M - $850.0M.
Acadia Healthcare earnings up next: Can turnaround weather policy shifts?
Acadia Healthcare (ACHC) is set to report first-quarter earnings, with analysts expecting $0.26 per share on $822.9 million in revenue, a significant rebound from the previous quarter. The company faces challenges including executive turnover, particularly the CFO departure, and potential headwinds from Medicaid reimbursement changes. Investors will be watching if Acadia can meet its reaffirmed guidance despite leadership changes and increasing payer scrutiny in the behavioral health sector.
Acadia Healthcare Company Inc. (ACHC): One of the Best Under-the-Radar Picks from David Einhorn
Acadia Healthcare Company, Inc. (ACHC) has been identified as a top under-the-radar pick by David Einhorn's Greenlight Capital, which has significantly increased its stake in the company. ACHC is the largest stand-alone behavioral healthcare provider in the U.S. and is pursuing aggressive expansion plans by adding more beds, which hedge funds see as a key driver for long-term organic growth and high-margin revenue.
Vanguard Portfolio Management holds 5.51% of Acadia Healthcare (ACHC)
Vanguard Portfolio Management has disclosed a 5.51% stake in Acadia Healthcare (ACHC) through a Schedule 13G SEC filing. This report indicates Vanguard beneficially owns 5,079,563 shares of common stock, with sole dispositive power over these shares and sole voting power over 18,125 shares. The filing, signed by Ashley Grim on April 28, 2026, details this passive investment by Vanguard and its affiliated entities.
